PharmAthene (NYSE:PIP)- Stocks Ensnare on Profitability Ratio: Cellectar Biosciences, Inc. (NASDAQ:CLRB)

PharmAthene, Inc. (NYSE:PIP) also in plain sight to attract passive investors, shares in most recent trading session surged remains unchanged after traded at $3.35.

While to figure out more clear vision, firm’s returns on investment calculated as -20.90%; it gives answer about efficiency of different investments in different securities. The returns on assets of firm also presenting perceptible condition of profitability, it has ROA of 221.80%, the very positive ratio starts from >+15% and very negative hits to <-15%.

The firm has noticeable volatility credentials; price volatility of stock was 4.89% for a week and 3.25% for a month. The performance of firm for the quarter recorded as 19.64% and for year stands at 105.52%, while the YTD performance was 3.08%. The co attains 0.11 for Average True Range for 14 days. The stock price of PIP is moving up from its 20 days moving average with 1.36% and isolated positively from 50 days moving average with 5.21%.

Cellectar Biosciences, Inc. (NASDAQ:CLRB) persists its position slightly strong in context of buying side, while shares price increased 12.32% during latest trading session. The returns on assets of firm also on noticeable level, it has ROA of -31.30%, which signifies how profitable a firm is relative to its total assets.

To make strengthen these views, the active industry firm has Quick Ratio of 4.30, which indicates firm has sufficient short-term assets to cover its immediate liabilities. In addition, the firm has debt to equity ratio of 0.03, sometimes its remain same with long term debt to equity ratio. Taking notice on volatility measures, price volatility of stock was 10.80% for a week and 9.39% for a month.


About Gerard Bergeron

Gerard Bergeron covers Bio-pharmacy or healthcare sector Press Releases news updates. He has extensive three year of experience in content writing as freelance writer. He performs analysis of Healthcare Companies and provides worthy information for investor community. He is an experienced writer with a precise grasp of the English language and a clear, compelling writing style.

Leave a Reply

Your email address will not be published. Required fields are marked *